• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.

作者信息

Birtcher Kim K, Allen Larry A, Anderson Jeffrey L, Bonaca Marc P, Gluckman Ty J, Hussain Aliza, Kosiborod Mikhail, Mehta Laxmi S, Virani Salim S

出版信息

J Am Coll Cardiol. 2023 Jan 24;81(3):292-317. doi: 10.1016/j.jacc.2022.08.754. Epub 2022 Oct 25.

DOI:10.1016/j.jacc.2022.08.754
PMID:36307329
Abstract
摘要

相似文献

1
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于整合动脉粥样硬化性心血管疾病与多重疾病治疗的专家共识决策路径：实用的、以患者为中心的护理框架报告
J Am Coll Cardiol. 2023 Jan 24;81(3):292-317. doi: 10.1016/j.jacc.2022.08.754. Epub 2022 Oct 25.
2
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会射血分数保留的心力衰竭管理专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19.
3
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.2020年2型糖尿病患者降低心血管风险新型疗法专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.
4
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会解决方案集监督委员会关于非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用的专家共识决策路径报告。
J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25.
5
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会关于心脏淀粉样变性患者综合多学科护理的专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. doi: 10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23.
6
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.2024年美国心脏病学会降低射血分数心力衰竭治疗专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2024 Apr 16;83(15):1444-1488. doi: 10.1016/j.jacc.2023.12.024. Epub 2024 Mar 8.
7
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.2020年美国心脏病学会解决方案集监督委员会报告：经皮冠状动脉介入治疗或患有动脉粥样硬化性心血管疾病的心房颤动或静脉血栓栓塞患者的抗凝和抗血小板治疗专家共识决策路径
J Am Coll Cardiol. 2021 Feb 9;77(5):629-658. doi: 10.1016/j.jacc.2020.09.011. Epub 2020 Nov 26.
8
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.2016年美国心脏病学会临床专家共识文件特别工作组报告：非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用专家共识决策路径
J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1.
9
New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia.用于管理动脉粥样硬化性心血管疾病风险的新胆固醇指南：2013年美国心脏病学会/美国心脏协会胆固醇指南与2014年美国国家脂质协会以患者为中心的血脂异常管理建议的比较
Cardiol Clin. 2015 May;33(2):181-96. doi: 10.1016/j.ccl.2015.02.001.
10
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017 年对 2016 年美国心脏病学会专家共识决策途径的重点更新：非他汀类药物在降低动脉粥样硬化性心血管疾病风险管理中的作用：美国心脏病学会专家组的专家共识决策途径报告。
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.

引用本文的文献

1
Lambl's Excrescences and Cardiac Papillary Fibroelastoma, an Unusual Cause of Embolic Strokes: Extended Data From a Single Center Case Series.兰布尔赘生物与心脏乳头状纤维弹性瘤——栓塞性中风的罕见病因：来自单中心病例系列的扩展数据
Cureus. 2025 Jul 31;17(7):e89162. doi: 10.7759/cureus.89162. eCollection 2025 Jul.
2
Effectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease.数字医疗对改善冠心病出院患者临床结局的有效性。
NPJ Digit Med. 2025 Jul 23;8(1):473. doi: 10.1038/s41746-025-01655-6.
3
Multimorbidity in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
急性冠状动脉综合征中的多种疾病共存：一项系统评价与荟萃分析
JACC Adv. 2025 Jul 22;4(8):102006. doi: 10.1016/j.jacadv.2025.102006.
4
Determinants of polypharmacy among ambulatory cardiovascular disease patients in Iluababora and Buno Bedele Zones, Ethiopia: prospective observational study.埃塞俄比亚伊卢阿巴博拉和布诺贝德莱地区门诊心血管疾病患者多重用药的决定因素：前瞻性观察研究
BMC Cardiovasc Disord. 2025 Jul 4;25(1):468. doi: 10.1186/s12872-025-04929-9.
5
Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular Events.前有心血管事件患者中PCSK9抑制剂单克隆抗体起始时间与临床结局的关系
Ther Clin Risk Manag. 2025 May 21;21:727-736. doi: 10.2147/TCRM.S512708. eCollection 2025.
6
Balancing polypharmacy and comorbidity management: cardiovascular health.平衡多重用药与共病管理：心血管健康
Curr Opin HIV AIDS. 2025 Jul 1;20(4):409-415. doi: 10.1097/COH.0000000000000948. Epub 2025 May 13.
7
Exploring Erythrina flavonoids as potential SARS-CoV-2 RdRp inhibitors through virtual screening, in silico ADMET evaluation, and molecular dynamics simulation studies.通过虚拟筛选、计算机辅助ADMET评估和分子动力学模拟研究探索刺桐属黄酮类化合物作为潜在的SARS-CoV-2 RdRp抑制剂。
Sci Rep. 2025 Apr 24;15(1):14259. doi: 10.1038/s41598-025-97311-w.
8
Effects of sodium tanshinone IIA sulfonate injection on pro-inflammatory cytokines, adhesion molecules and chemokines in Chinese patients with atherosclerosis and atherosclerotic cardiovascular disease: a meta-analysis of randomized controlled trials.丹参酮IIA磺酸钠注射液对中国动脉粥样硬化及动脉粥样硬化性心血管疾病患者促炎细胞因子、黏附分子及趋化因子的影响：一项随机对照试验的荟萃分析
Front Cardiovasc Med. 2025 Feb 13;12:1511747. doi: 10.3389/fcvm.2025.1511747. eCollection 2025.
9
Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常运动员参与竞技运动的临床考量：美国心脏协会和美国心脏病学会的科学声明
J Am Coll Cardiol. 2025 Mar 18;85(10):1059-1108. doi: 10.1016/j.jacc.2024.12.025. Epub 2025 Feb 20.
10
Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.非传统动脉粥样硬化疾病中的残余传统风险。
Int J Mol Sci. 2025 Jan 10;26(2):535. doi: 10.3390/ijms26020535.